Aspartate Aminotransferase to Platelet Ratio Index and Fibrosis-4 Index for Detecting Liver Fibrosis in Patients With Autoimmune Hepatitis: A Meta-Analysis.
APRI
FIB-4
autoimmune hepatitis
liver fibrosis
noninvasive methods
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2022
2022
Historique:
received:
09
03
2022
accepted:
21
04
2022
entrez:
6
6
2022
pubmed:
7
6
2022
medline:
9
6
2022
Statut:
epublish
Résumé
Aspartate aminotransferase-to-platelet ratio index (APRI) and fibrosis-4 index (FIB-4) are the two most widely studied noninvasive markers of liver fibrosis. We aimed to assess the diagnostic accuracy of APRI and FIB-4 for liver fibrosis in patients with autoimmune hepatitis (AIH) using liver biopsy as the reference standard. PubMed, EMBASE, Cochrane Library and Web of Science databases were searched for studies (published as of May 1st, 2021) that assessed the diagnostic performance of APRI and FIB-4 for liver fibrosis in AIH. The summary area under receiver operating characteristics curve (AUROC), sensitivity, specificity, diagnostic odds ratios were used to assess the diagnostic accuracy of APRI and FIB-4 for detecting liver fibrosis. Fourteen studies (including 1015 patients) were selected with 13 studies each evaluating the use of APRI and FIB-4 for detecting different stages of fibrosis in AIH. For prediction of significant fibrosis, advanced fibrosis, and cirrhosis, the summary AUROC value was 0.66 [95% confidence interval (CI): 0.61-0.70], 0.71 (95% CI: 0.67-0.75), and 0.75 (95% CI: 0.71-0.79) for APRI, and the summary AUROC value was 0.75 (95% CI: 0.71-0.79), 0.73 (95% CI: 0.69-0.77) and 0.79 (95% CI: 0.75-0.82) for FIB-4, respectively. The summary sensitivity and specificity for diagnosis of significant fibrosis, advanced fibrosis, and cirrhosis were 90% and 36%, 78% and 55%, and 77% and 61% for APRI, and 70% and 70%, 65% and 70%, and 78% and 65% for FIB-4, respectively. APRI and FIB-4 showed suboptimal diagnostic performance for identifying liver fibrosis in AIH with mediocre sensitivity and specificity.
Sections du résumé
Background
Aspartate aminotransferase-to-platelet ratio index (APRI) and fibrosis-4 index (FIB-4) are the two most widely studied noninvasive markers of liver fibrosis. We aimed to assess the diagnostic accuracy of APRI and FIB-4 for liver fibrosis in patients with autoimmune hepatitis (AIH) using liver biopsy as the reference standard.
Methods
PubMed, EMBASE, Cochrane Library and Web of Science databases were searched for studies (published as of May 1st, 2021) that assessed the diagnostic performance of APRI and FIB-4 for liver fibrosis in AIH. The summary area under receiver operating characteristics curve (AUROC), sensitivity, specificity, diagnostic odds ratios were used to assess the diagnostic accuracy of APRI and FIB-4 for detecting liver fibrosis.
Results
Fourteen studies (including 1015 patients) were selected with 13 studies each evaluating the use of APRI and FIB-4 for detecting different stages of fibrosis in AIH. For prediction of significant fibrosis, advanced fibrosis, and cirrhosis, the summary AUROC value was 0.66 [95% confidence interval (CI): 0.61-0.70], 0.71 (95% CI: 0.67-0.75), and 0.75 (95% CI: 0.71-0.79) for APRI, and the summary AUROC value was 0.75 (95% CI: 0.71-0.79), 0.73 (95% CI: 0.69-0.77) and 0.79 (95% CI: 0.75-0.82) for FIB-4, respectively. The summary sensitivity and specificity for diagnosis of significant fibrosis, advanced fibrosis, and cirrhosis were 90% and 36%, 78% and 55%, and 77% and 61% for APRI, and 70% and 70%, 65% and 70%, and 78% and 65% for FIB-4, respectively.
Conclusions
APRI and FIB-4 showed suboptimal diagnostic performance for identifying liver fibrosis in AIH with mediocre sensitivity and specificity.
Identifiants
pubmed: 35663945
doi: 10.3389/fimmu.2022.892454
pmc: PMC9157437
doi:
Substances chimiques
Aspartate Aminotransferases
EC 2.6.1.1
Types de publication
Journal Article
Meta-Analysis
Langues
eng
Sous-ensembles de citation
IM
Pagination
892454Informations de copyright
Copyright © 2022 Dong, Chen, Lyu and Yang.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
PLoS Med. 2009 Jul 21;6(7):e1000100
pubmed: 19621070
Hepatology. 2011 Mar;53(3):726-36
pubmed: 21319189
J Clin Transl Hepatol. 2020 Jun 28;8(2):143-149
pubmed: 32832394
Hepatology. 2007 Sep;46(3):912-21
pubmed: 17705266
Hepatology. 2020 Aug;72(2):671-722
pubmed: 31863477
Clin Chim Acta. 2018 Nov;486:135-141
pubmed: 30036523
J Gastroenterol Hepatol. 2017 Mar;32(3):639-644
pubmed: 27505153
Hepatol Int. 2019 Jan;13(1):91-101
pubmed: 30443702
World J Clin Cases. 2019 Aug 6;7(15):2022-2037
pubmed: 31423434
BMC Infect Dis. 2020 May 25;20(1):372
pubmed: 32450844
Med Sci Monit. 2020 Nov 12;26:e927946
pubmed: 33180750
Expert Rev Gastroenterol Hepatol. 2020 Jul;14(7):631-638
pubmed: 32510248
J Gastroenterol Hepatol. 2016 Dec;31(12):1956-1962
pubmed: 27059170
Liver Int. 2019 Jun;39(6):1002-1013
pubmed: 30716203
Mini Rev Med Chem. 2009 Jun;9(7):847-60
pubmed: 19519509
Hepatology. 2015 Jan;61(1):292-302
pubmed: 25132233
Liver Int. 2014 Feb;34 Suppl 1:91-6
pubmed: 24373084
Hepatol Res. 2016 Jun;46(7):613-21
pubmed: 26406984
J Hepatol. 2014 Jan;60(1):210-23
pubmed: 24084655
Hepatology. 2017 Nov;66(5):1486-1501
pubmed: 28586172
Ann Intern Med. 2011 Oct 18;155(8):529-36
pubmed: 22007046
World J Gastroenterol. 2021 Jun 14;27(22):2994-3009
pubmed: 34168403
J Dig Dis. 2020 Mar;21(3):127-138
pubmed: 32108989
Hepatology. 2004 Jun;39(6):1631-8
pubmed: 15185304
J Hepatol. 2016 Apr;64(4):773-80
pubmed: 26626497
Liver Int. 2018 Sep;38(9):1562-1570
pubmed: 29314613
World J Gastroenterol. 2005 Mar 28;11(12):1862-6
pubmed: 15793882
J Hepatol. 2015 Oct;63(4):971-1004
pubmed: 26341719
J Gastroenterol Hepatol. 2019 Oct;34(10):1676-1684
pubmed: 31146297
PLoS One. 2019 Mar 11;14(3):e0212771
pubmed: 30856201
Eur J Gastroenterol Hepatol. 2019 Nov;31(11):1467-1474
pubmed: 31107735
Liver Int. 2021 Feb;41(2):348-356
pubmed: 33159831
Medicine (Baltimore). 2020 Aug 21;99(34):e21408
pubmed: 32846758
Clin Mol Hepatol. 2021 Jan;27(1):58-69
pubmed: 33291862
Aliment Pharmacol Ther. 2017 Mar;45(5):723-732
pubmed: 28004405
Gut Liver. 2020 Jul 15;14(4):430-438
pubmed: 32301319
J Clin Lab Anal. 2019 Sep;33(7):e22922
pubmed: 31115929
World J Gastroenterol. 2017 Feb 7;23(5):859-868
pubmed: 28223730
J Dig Dis. 2020 Sep;21(9):519-525
pubmed: 32700794
Med Sci Monit. 2017 Oct 26;23:5106-5112
pubmed: 29073121
J Gastroenterol. 2011 Jan;46 Suppl 1:56-62
pubmed: 21042923
Aliment Pharmacol Ther. 2016 Feb;43(4):458-69
pubmed: 26669632
Saudi J Gastroenterol. 2006 Apr-Jun;12(2):73-6
pubmed: 19858589
Expert Rev Gastroenterol Hepatol. 2021 Sep;15(9):1077-1089
pubmed: 33487039
Hepat Mon. 2016 Oct 31;16(11):e40737
pubmed: 28070199
Hepatology. 2003 Aug;38(2):518-26
pubmed: 12883497
Hepatology. 2006 Jun;43(6):1317-25
pubmed: 16729309